Search Page

1

Cite

Share

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus.

Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Polidori D, et al. Among authors: rothenberg p. J Clin Endocrinol Metab. 2013 May;98(5):E867-71. doi: 10.1210/jc.2012-4205. Epub 2013 Apr 12. J Clin Endocrinol Metab. 2013. PMID: 23585665 Free PMC article. Clinical Trial.

Cite

Share

2

Cite

Share

Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.

Sha S, Polidori D, Farrell K, Ghosh A, Natarajan J, Vaccaro N, Pinheiro J, Rothenberg P, Plum-Mörschel L. Sha S, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2015 Feb;17(2):188-97. doi: 10.1111/dom.12418. Epub 2015 Jan 5. Diabetes Obes Metab. 2015. PMID: 25421015 Free PMC article. Clinical Trial.

Cite

Share

3

Cite

Share

Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.

Sha S, Polidori D, Heise T, Natarajan J, Farrell K, Wang SS, Sica D, Rothenberg P, Plum-Mörschel L. Sha S, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2014 Nov;16(11):1087-95. doi: 10.1111/dom.12322. Epub 2014 Jul 8. Diabetes Obes Metab. 2014. PMID: 24939043 Clinical Trial.

Cite

Share

4

Cite

Share

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.

Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Sha S, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2011 Jul;13(7):669-72. doi: 10.1111/j.1463-1326.2011.01406.x. Diabetes Obes Metab. 2011. PMID: 21457428 Clinical Trial.

Cite

Share

5

Cite

Share

CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

Di Prospero NA, Artis E, Andrade-Gordon P, Johnson DL, Vaccaro N, Xi L, Rothenberg P. Di Prospero NA, et al. Among authors: rothenberg p. Diabetes Obes Metab. 2014 Nov;16(11):1055-64. doi: 10.1111/dom.12309. Epub 2014 May 25. Diabetes Obes Metab. 2014. PMID: 24798870 Clinical Trial.

Cite

Share

6

Cite

Share

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.

Devineni D, Manitpisitkul P, Vaccaro N, Bernard A, Skee D, Mamidi RN, Tian H, Weiner S, Stieltjes H, Sha S, Rothenberg P. Devineni D, et al. Among authors: rothenberg p. Int J Clin Pharmacol Ther. 2015 Jan;53(1):41-53. doi: 10.5414/CP202157. Int J Clin Pharmacol Ther. 2015. PMID: 25345427 Clinical Trial.

Cite

Share

7

Cite

Share

Absolute oral bioavailability and pharmacokinetics of canagliflozin: A microdose study in healthy participants.

Devineni D, Murphy J, Wang SS, Stieltjes H, Rothenberg P, Scheers E, Mamidi RN. Devineni D, et al. Among authors: rothenberg p. Clin Pharmacol Drug Dev. 2015 Jul;4(4):295-304. doi: 10.1002/cpdd.162. Epub 2014 Dec 11. Clin Pharmacol Drug Dev. 2015. PMID: 27136910 Clinical Trial.

Cite

Share

8

Cite

Share

Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants.

Devineni D, Manitpisitkul P, Murphy J, Stieltjes H, Ariyawansa J, Di Prospero NA, Rothenberg P. Devineni D, et al. Among authors: rothenberg p. Clin Pharmacol Drug Dev. 2015 Jul;4(4):279-86. doi: 10.1002/cpdd.151. Epub 2014 Dec 11. Clin Pharmacol Drug Dev. 2015. PMID: 27136908 Clinical Trial.

Cite

Share

9

Cite

Share

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on C-peptide kinetics.

Polidori D, Sha S, Heise T, Natarajan J, Artis E, Wang SS, Vaccaro N, Rothenberg P, Stirban A. Polidori D, et al. Among authors: rothenberg p. Clin Pharmacol Drug Dev. 2015 Jan;4(1):12-7. doi: 10.1002/cpdd.115. Epub 2014 May 28. Clin Pharmacol Drug Dev. 2015. PMID: 27127999 Clinical Trial.

Cite

Share

10

Cite

Share

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Rosenthal N, Meininger G, Ways K, Polidori D, Desai M, Qiu R, Alba M, Vercruysse F, Balis D, Shaw W, Edwards R, Bull S, Di Prospero N, Sha S, Rothenberg P, Canovatchel W, Demarest K. Rosenthal N, et al. Among authors: rothenberg p. Ann N Y Acad Sci. 2015 Nov;1358:28-43. doi: 10.1111/nyas.12852. Epub 2015 Aug 25. Ann N Y Acad Sci. 2015. PMID: 26305874 Review.

Cite

Share